4479

Adoptive Ex-Vivo Neuro-Immunotherapy for Cancer

LEVITE Mia, HUJI

 

Category

LifeSciences and BioTechnology   

Keywords

Cancer, Neuro-Immunotherapy, HNC, HCC

Current development stage

TRL3 - Hypothesis testing and initial POC is demonstrated in limited number of in-vitro models

 

Application

Neuro-Immunotherapy is based on safe, rapid and potent ex-vivo treatment of the patient’s own T cells, by physiological neurotransmitters and neuropeptides, at low physiological concentrations, and then their repeated administration back to the patient, over time, for as long as needed.

It was found that specific neurotransmitters and neuropeptides by themselves and their combinations increase directly and potently the adhesion, chemotactic migration and cytokine secretion of human T cells of healthy subjects.

Our Innovation

Neuro-Immunotherapy protocol based on safe, rapid and potent ex-vivo treatment of the patient’s own T cells, by physiological neurotransmitters and neuropeptides, at low physiological concentrations, and then their repeated administration back to the patient, over time, for as long as needed.

Method and treatment protocol for improving T-cell therapeutic potential in against cancer and infectious organisms.  The effect of the specific neurotransmitters, neuropeptides and their combinations on human T cells are direct, rapid, and potent. Without the need of any additional stimuli.

The protocol of the adoptive Neuro-Immunotherapy includes the creation of the ‘Personalized T cells Bank’ for each patient, in which aliquots of the patient’s T cells will be kept frozen in liquid nitrogen. This bank serves for further researcher and any other future therapeutic need of the patient’s T cells.

Advantages

  • Fits any cancer
  • Does NOT require the collection of tumor-specific T-cells from patients nor artificial cell growth
  • Minimal expected side effects

Technology

The adoptive Neuro-Immunotherapy is reduced to two stages, which are both patient-tailored. In the first stage there is a double selection: a) of the candidate patients that are likely to benefit from the Neuro-Immunotherapy, and b) of the most effective neurotransmitter-neuropeptide combination that can augment substantially the survival and anti-cancer activity of their own T cells. In the second stage, a patient’s own T cells will be then purified from their own leukocytes, and aliquoted, and by doing so a patient’s own T cell bank will be created.

Opportunity

The adoptive Neuro-Immunotherapy is easier, quicker and more patient-friendly than any other currently used adoptive immunotherapy of cancer. The Neuro-Immunotherapy, if successful, may minimize cancer recurrence and save lives, and may make subsequent harmful and expensive treatments unnecessary.

 

 

 

 

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608
Contact ME:
Image CAPTCHA